Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to ...

Key Insights Significant control over IO Biotech by private equity firms implies that the general public has more ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Love her or hate her, Cathie Wood is a true maverick who’s made a name finding tomorrow’s big disruptors long before anyone ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Discover why IBB's focused approach makes it preferable to XBI. Learn about their objectives, diversification, and ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...